Chairman: *Dr Dave Boyd* (Johnson Matthey)

1 July 2010, 10h00 – 11h00

**Participants:**

| | |
|---|---|
| Dave Boyd | – Johnson Matthey, United Kingdom |
| Caroline Braibant | – EPMF, Belgium |
| Mike Halhead | – Anglo Platinum, South Africa |
| Mark Raffray | – Johnson Matthey, United Kingdom |
| Klaus Rothenbacher | – EPMF, United Kingdom |
| Mike Shepherd | – Vale Inco, United Kingdom |
| Chantre Viviers | – Heraeus, Germany |
| Heinz-Gunter Schenzel | – Carl Hafner, Germany |

**Agenda:**

1. Proposal for sample accounting
2. Summary table by Dave Boyd on substance state/water solubility
3. Recommendation for water solubility testing
4. Proposal on potential sensitisation endpoint for Palladium (II) di (4-oxopent-2-en-2-oate)

## 1. Sample accounting/reimbursement strategy

The draft document on sample accounting was agreed in principle. Suggestions for improvement were made (see Annex 1). It was recommended to prepare a sample trail template to be used by all testing houses working with PMC (see Appendix A of Annex 1).

***Actions by COB 2 July 2010***

- PMC to update Sample Accounting document and prepare Sample Trailing template and circulate to the group for comments before submission to Management Committee for completion/approval
- Following approval by Management Committee, PMC to send Harlan Sample Accounting and Sample Trailing template
- Members to suggest name of potential Recovery company interested in analysing and recovering PM and Re contents of mixed tested materials and assisting PMC secretariat with reimbursement of sample costs

## 2. Water solubility testing

A summary table (Annex 2), kindly prepared by D. Boyd, was presented (some Members may not have received the table due to an error in e-mail transmission). The table proposes a testing plan for water solubility testing. In order to bring the testing costs to half, Johnson Matthey offered to carry out water solubility tests for those substances having a solubility > 10 g/l (marked in blue in the table) at their Technology Centre (JMTC).

The following issues were discussed:

- Solubility test protocol: JMTC can perform solubility tests on materials which have a solubility of > 0,02 g/l (JMTC cannot perform the column elution method and has reservations on its applicability to most of the PGM materials)
- Testing performed at JMTC and potential confidentiality issues: Carl Hafner and Vale Inco support JMTC's proposal. Umicore and Heraeus will be invited to comment on this proposal by COB 2 July 2010 (see below). If all Lead Registrants/Sample Providers have expressed a positive opinion about JMTC's offer, JMTC will prepare a formal testing proposal clarifying testing conditions, cost, protection of confidential information, commitment to publish, etc.
- Test item: although REACH does not distinguish anhydrous from hydrated forms of the same substance or dry forms from aqueous solutions of substances, there may be a difference in species to be considered during the testing programme. It was suggested that for solubility and solubility-related tests the hydrated form, when it exists, should also be preferred to the anhydrous form (worst case approach).

Chairman: *Dr Dave Boyd* (Johnson Matthey)

1 July 2010, 10h00 – 11h00

***Actions by COB 2 July 2010***
- PMC to request opinion on JMTC's offer from Umicore and Heraeus
- Umicore and Heraeus to inform PMC on opinion
- If feed-back positive, PMC to request formal quote from JMTC
- Mark Raffray to circulate recent ECHA ruling on testing of solutions
- PMC to clarify applicability of column elution protocol on precious metal compounds and possibility of performing screening T/D tests instead with WCA and Harlan

## 3. State of substance and Sample providers

As highlighted in red in Annex 2, there still are some outstanding questions related to the physical state of some substances. These questions have been raised with the relevant Members (only one response so far). The answers to these questions as well as the identification of Lead Registrants/Sample Providers are key to launch the CLP testing programme (foreseen on 15 July 2010). As soon as the answers to these questions have been received, a final PGM inventory will be sent to WCA (and JMTC) in order to finalise the scope of the testing programme(s) and launch the sample collection.

***Actions for w/c 12 July 2010***
- PMC to remind companies on deadline to revert with answers to questions (9 July; not specified in original e-mail)
- PMC to update PGM inventory and send to WCA (and JMTC) as support to finalise testing programme(s)
- PMC to circulate final CLP testing programme for final discussion and approval

## 4. Sensitisation

PMC received a question as to the potential sensitising effects of Palladium (II) di (4-oxopent-2-en-2-oate) and how to handle this for the CLP notification. This substance is referred to as "Substance 2" in the recent reports by WCA and BIBRA (available upon request). PMC has not finalised the review of the Phase II reports by WCA/BIBRA yet but have specifically checked with them on this specific point.

WCA advises that there is no data on this endpoint for this specific substance but that they propose to read across from other Pd (II) substances for this endpoint. The read across indicates that the substance is a contact skin sensitiser, which confirms the participants' views that extensive evidence indicating that soluble Pd (II) salts are contact sensitizers exists.

It was therefore suggested to work on an inclusive basis where the default classification should be that soluble Pd (II) compounds are always contact skin sensitisers. In case of a potential exception, testing should only be engaged if there are properly documented reasons and justifications to believe that a given soluble Pd(II) compound is not a contact skin sensitiser.

***Actions by COB 2 July 2010***
- PMC to circulate the relevant discussion in the IPCS EHC monograph 226 to the concerned company and WCA
- PMC to inform the concerned company on the above conclusion
- PMC to clarify to Members and WCA that CLP notifications prepared for soluble Pd(II) compounds will always carry a default classification as contact skin sensitiser

**Annexes**
1. Sample accounting document
1.1. Appendix A of Sample accounting document : Sample trailing template
2. JMTC's proposed water solubility testing programme

Avenue de Broqueville, 12 – BE-1150 Brussels
**Tel.**: +32 2 775 63 23 **Fax:** +32 2 779 05 23 **Mobile:** +32 473 52 52 73
**E-mail:** braibant@epmf.be **Website:** www.epmf.be